Nonacidic Chemotype Possessing N‑Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists

Farnesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmaco...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2018-02, Vol.9 (2), p.78-83
Main Authors: Teno, Naoki, Yamashita, Yukiko, Iguchi, Yusuke, Fujimori, Ko, Une, Mizuho, Nishimaki-Mogami, Tomoko, Hiramoto, Takie, Gohda, Keigo
Format: Article
Language:English
Subjects:
Letter
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a523t-def843a46759acbc1b0b9cc5ce0b4ff5ee0e72be18ff2849b1b0e3cd8facd8443
cites cdi_FETCH-LOGICAL-a523t-def843a46759acbc1b0b9cc5ce0b4ff5ee0e72be18ff2849b1b0e3cd8facd8443
container_end_page 83
container_issue 2
container_start_page 78
container_title ACS medicinal chemistry letters
container_volume 9
creator Teno, Naoki
Yamashita, Yukiko
Iguchi, Yusuke
Fujimori, Ko
Une, Mizuho
Nishimaki-Mogami, Tomoko
Hiramoto, Takie
Gohda, Keigo
description Farnesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmacokinetics. We describe herein a structure–activity relationship (SAR) exploration of nonacidic FXR antagonist 6 focusing on two regions in the structure and biological evaluation of nonacidic 10 with the characteristic N-acylated piperidine group obtained from SAR studies. As the robust affinity to FXR is feasible with our nonacidic analogue, 10 is among the most promising candidates for in vivo testing.
doi_str_mv 10.1021/acsmedchemlett.7b00363
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5807871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2004368095</sourcerecordid><originalsourceid>FETCH-LOGICAL-a523t-def843a46759acbc1b0b9cc5ce0b4ff5ee0e72be18ff2849b1b0e3cd8facd8443</originalsourceid><addsrcrecordid>eNqFkc9qGzEQh0VJaNK0r2B0TA52pV1ppb0UjKnbQP5hWvBNaLWzjsJa2kpywbe-Ql4xTxIFu8E55SIJ9M03w_wQGlEyoaSgX7WJa2jNPax7SGkiGkLKqvyATmnN5JhLwY8O3ifoU4wPhFS1EOQjOilqxitR01PkbrzTxrbW4FmW-bQdAN_5GCFG61b45unf49Rse52gxXd2gJBZB_jaW0hbrGOGE7iE5zo4iN62eIkXYGBIPuDz-XJxgacu6ZV3Nqb4GR13uo_wZX-fod_z779mP8dXtz8uZ9OrseZFmcYtdJKVmlWC19o0hjakqY3hBkjDuo4DEBBFA1R2XSFZ3WQAStPKTueDsfIMfdt5h03zsqc8YdC9GoJd67BVXlv19sfZe7XyfxWXREhBs-B8Lwj-zwZiUmsbDfS9duA3URWEsLKSpOYZrXaoCXlvAbrXNpSol7DU27DUPqxcODoc8rXsfzoZKHZAFqgHvwku7-w96zNBbqsq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2004368095</pqid></control><display><type>article</type><title>Nonacidic Chemotype Possessing N‑Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><source>PubMed Central</source><creator>Teno, Naoki ; Yamashita, Yukiko ; Iguchi, Yusuke ; Fujimori, Ko ; Une, Mizuho ; Nishimaki-Mogami, Tomoko ; Hiramoto, Takie ; Gohda, Keigo</creator><creatorcontrib>Teno, Naoki ; Yamashita, Yukiko ; Iguchi, Yusuke ; Fujimori, Ko ; Une, Mizuho ; Nishimaki-Mogami, Tomoko ; Hiramoto, Takie ; Gohda, Keigo</creatorcontrib><description>Farnesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmacokinetics. We describe herein a structure–activity relationship (SAR) exploration of nonacidic FXR antagonist 6 focusing on two regions in the structure and biological evaluation of nonacidic 10 with the characteristic N-acylated piperidine group obtained from SAR studies. As the robust affinity to FXR is feasible with our nonacidic analogue, 10 is among the most promising candidates for in vivo testing.</description><identifier>ISSN: 1948-5875</identifier><identifier>EISSN: 1948-5875</identifier><identifier>DOI: 10.1021/acsmedchemlett.7b00363</identifier><identifier>PMID: 29456791</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Letter</subject><ispartof>ACS medicinal chemistry letters, 2018-02, Vol.9 (2), p.78-83</ispartof><rights>Copyright © 2018 American Chemical Society</rights><rights>Copyright © 2018 American Chemical Society 2018 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a523t-def843a46759acbc1b0b9cc5ce0b4ff5ee0e72be18ff2849b1b0e3cd8facd8443</citedby><cites>FETCH-LOGICAL-a523t-def843a46759acbc1b0b9cc5ce0b4ff5ee0e72be18ff2849b1b0e3cd8facd8443</cites><orcidid>0000-0002-2506-0769 ; 0000-0002-3940-5473</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807871/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807871/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29456791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Teno, Naoki</creatorcontrib><creatorcontrib>Yamashita, Yukiko</creatorcontrib><creatorcontrib>Iguchi, Yusuke</creatorcontrib><creatorcontrib>Fujimori, Ko</creatorcontrib><creatorcontrib>Une, Mizuho</creatorcontrib><creatorcontrib>Nishimaki-Mogami, Tomoko</creatorcontrib><creatorcontrib>Hiramoto, Takie</creatorcontrib><creatorcontrib>Gohda, Keigo</creatorcontrib><title>Nonacidic Chemotype Possessing N‑Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists</title><title>ACS medicinal chemistry letters</title><addtitle>ACS Med. Chem. Lett</addtitle><description>Farnesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmacokinetics. We describe herein a structure–activity relationship (SAR) exploration of nonacidic FXR antagonist 6 focusing on two regions in the structure and biological evaluation of nonacidic 10 with the characteristic N-acylated piperidine group obtained from SAR studies. As the robust affinity to FXR is feasible with our nonacidic analogue, 10 is among the most promising candidates for in vivo testing.</description><subject>Letter</subject><issn>1948-5875</issn><issn>1948-5875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkc9qGzEQh0VJaNK0r2B0TA52pV1ppb0UjKnbQP5hWvBNaLWzjsJa2kpywbe-Ql4xTxIFu8E55SIJ9M03w_wQGlEyoaSgX7WJa2jNPax7SGkiGkLKqvyATmnN5JhLwY8O3ifoU4wPhFS1EOQjOilqxitR01PkbrzTxrbW4FmW-bQdAN_5GCFG61b45unf49Rse52gxXd2gJBZB_jaW0hbrGOGE7iE5zo4iN62eIkXYGBIPuDz-XJxgacu6ZV3Nqb4GR13uo_wZX-fod_z779mP8dXtz8uZ9OrseZFmcYtdJKVmlWC19o0hjakqY3hBkjDuo4DEBBFA1R2XSFZ3WQAStPKTueDsfIMfdt5h03zsqc8YdC9GoJd67BVXlv19sfZe7XyfxWXREhBs-B8Lwj-zwZiUmsbDfS9duA3URWEsLKSpOYZrXaoCXlvAbrXNpSol7DU27DUPqxcODoc8rXsfzoZKHZAFqgHvwku7-w96zNBbqsq</recordid><startdate>20180208</startdate><enddate>20180208</enddate><creator>Teno, Naoki</creator><creator>Yamashita, Yukiko</creator><creator>Iguchi, Yusuke</creator><creator>Fujimori, Ko</creator><creator>Une, Mizuho</creator><creator>Nishimaki-Mogami, Tomoko</creator><creator>Hiramoto, Takie</creator><creator>Gohda, Keigo</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2506-0769</orcidid><orcidid>https://orcid.org/0000-0002-3940-5473</orcidid></search><sort><creationdate>20180208</creationdate><title>Nonacidic Chemotype Possessing N‑Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists</title><author>Teno, Naoki ; Yamashita, Yukiko ; Iguchi, Yusuke ; Fujimori, Ko ; Une, Mizuho ; Nishimaki-Mogami, Tomoko ; Hiramoto, Takie ; Gohda, Keigo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a523t-def843a46759acbc1b0b9cc5ce0b4ff5ee0e72be18ff2849b1b0e3cd8facd8443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teno, Naoki</creatorcontrib><creatorcontrib>Yamashita, Yukiko</creatorcontrib><creatorcontrib>Iguchi, Yusuke</creatorcontrib><creatorcontrib>Fujimori, Ko</creatorcontrib><creatorcontrib>Une, Mizuho</creatorcontrib><creatorcontrib>Nishimaki-Mogami, Tomoko</creatorcontrib><creatorcontrib>Hiramoto, Takie</creatorcontrib><creatorcontrib>Gohda, Keigo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teno, Naoki</au><au>Yamashita, Yukiko</au><au>Iguchi, Yusuke</au><au>Fujimori, Ko</au><au>Une, Mizuho</au><au>Nishimaki-Mogami, Tomoko</au><au>Hiramoto, Takie</au><au>Gohda, Keigo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nonacidic Chemotype Possessing N‑Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists</atitle><jtitle>ACS medicinal chemistry letters</jtitle><addtitle>ACS Med. Chem. Lett</addtitle><date>2018-02-08</date><risdate>2018</risdate><volume>9</volume><issue>2</issue><spage>78</spage><epage>83</epage><pages>78-83</pages><issn>1948-5875</issn><eissn>1948-5875</eissn><abstract>Farnesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmacokinetics. We describe herein a structure–activity relationship (SAR) exploration of nonacidic FXR antagonist 6 focusing on two regions in the structure and biological evaluation of nonacidic 10 with the characteristic N-acylated piperidine group obtained from SAR studies. As the robust affinity to FXR is feasible with our nonacidic analogue, 10 is among the most promising candidates for in vivo testing.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>29456791</pmid><doi>10.1021/acsmedchemlett.7b00363</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-2506-0769</orcidid><orcidid>https://orcid.org/0000-0002-3940-5473</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1948-5875
ispartof ACS medicinal chemistry letters, 2018-02, Vol.9 (2), p.78-83
issn 1948-5875
1948-5875
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5807871
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list); PubMed Central
subjects Letter
title Nonacidic Chemotype Possessing N‑Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A26%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nonacidic%20Chemotype%20Possessing%20N%E2%80%91Acylated%20Piperidine%20Moiety%20as%20Potent%20Farnesoid%20X%20Receptor%20(FXR)%20Antagonists&rft.jtitle=ACS%20medicinal%20chemistry%20letters&rft.au=Teno,%20Naoki&rft.date=2018-02-08&rft.volume=9&rft.issue=2&rft.spage=78&rft.epage=83&rft.pages=78-83&rft.issn=1948-5875&rft.eissn=1948-5875&rft_id=info:doi/10.1021/acsmedchemlett.7b00363&rft_dat=%3Cproquest_pubme%3E2004368095%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a523t-def843a46759acbc1b0b9cc5ce0b4ff5ee0e72be18ff2849b1b0e3cd8facd8443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2004368095&rft_id=info:pmid/29456791&rfr_iscdi=true